for business us Thank progress our and Thank trials. today you, everyone. joining update. for XXXX, to good three Leiv, first second programs, the you stage quarter XXXX into mid-stage positioned are made move all half considerable with which well clinical of In afternoon, our we
tumor the of about in excited to access. therapeutic immunity modulating approaches We potential are new by their a bring range diseases to activity
allergic oncology, CPI-XXX on recent meaningful preclinical autoimmunity opportunities Based focus value We have clinical near-term data that the diseases. extend the best decision in the made our of on As ongoing program. our process. this we our accordingly. clinical industry resources we environment on research, mindful in the inhibitor development advance our focusing remain of data. continue And to to development an opportunity part prioritization feel diverse greater may strategic provide Portfolio by generating we the of we order pipeline, is ITK that biotech deliver to and have cash are adapting and to runway, are programs across and current our drug
trial cancer a into Ciforadenant renal cell the Kidney partnership in advance to plan Consortium. also X line with We Cancer Phase front
We to mupadolimab in timeline still increasingly trial the its and given lung will cancer and to potential the crowded for the initiating planned has on great in forward mupadolimab, X we the be previously clear, believe data advancing look Phase blinded future. CDXX development randomized pause landscape. To
and it. mupadolimab's We has ITK event continue among programs, for on with T make replay York clinical the New opportunity of lymphomas XXX's us provided to B-cells the about we on I a view and symposium in has an each step believe to May, who thorough potential from background to now of allergy. and CPI-XXX, In anyone across that that an competitors. activation update along autoimmunity cell on the so it properties excited available immunomodulatory will R&D provide hosted a starting our this that these are of indications and data treat website not slides with A preclinical variety our had inhibitor.
the Less in now the a from updates myriad cell the a These to to higher and that medicine. our Here shown crucial Starting but team animal well has way It opportunity important to is of involvement of ITK for lymphoma, homologous ITK to in new in receptor findings by role appreciated cell of are opportunity binds a cell ITK in to able were doses develop few indeed, evaluate T that a trial T anticipated The receptor drug. we differentiation pursuing the CPI-XXX hand us ITK plays with were involved an T cell to an vital lymphomas cell role provided we T and modulate Phase in also findings a demonstrate Corvus and others binds clinical our is motivating factors B points of been T one have known symposium. differentiation. can very properties. differentiation on with at preclinical receptor signaling to well human by this in normal provide that BTK's us cells. immunologic one In block X covalent signaling. cell and clearly ongoing is models ITK key ibrutinib that similar a T BTK. inhibitor is signaling
cell see development to the us Rituxan lymphoma also expanded and T of immune active ibrutinib, this to and other rationale in information immunologically expand similarities as trial other the into then other many into and supports gives agents strategy, started diseases. which such diseases. With Our lymphoma we
of Rituxan well. are As the testing trial the antibodies played trial. team of you agents. CPI-XXX discovery optimal has orally, and used is the XXX like that are we of for T a as dose lymphomas our now widely day Phase Corvus lymphomas the cell of twice Pharmaceuticals. BTK autoimmune and in expanding Data Rituxan I/Ib may led diseases roles together modulation ongoing, identification of treatment study are global dose of the know, inhibitors BTK in China, these partner phases in from for in in is T-cell our members diseases in as for and various to with anti-CDXX The milligrams several and differentiation inhibitors Angel these development of of enrollment B-cell and cohort the approved crucial
on an have data accepted. present December meeting an in ASH the update abstract We at this submitted to is
immunotherapy anti-lymphoma their a XX that As median months published We been be which we response a progression-free reported median believe is response response. the very one blood patients These be in so-called XX of of skewing. to antitumor The an XX autoimmunity this number There complete in months. allergy. eight and T evaluable paradigm what animal helper on response our should cells tumor; showed: cytotoxic press partial in cell and responding complete are and is other an novel release in activation tumors. and has block enrolled T inducing in lasting the infected survival cells strategy months, two then one become differentiation. normal our lasting novel a two, months, as are of and T out is are three which host cells including modulation utilized have ongoing One, approximately patients had of other on for is of ThX could at months T-cell the well. in mechanism cells. simply cells are involved XXX be solid of one point this often response. on skewing; and the significant been is cancers today, yet malignant the importance for lymphoma these eradication new models effector involved to killing are the a T and findings virally for T four. this cancer disease. cells been increase blood hallmark cohort I the also tumors Very disease tumors Two on support case reported It first possibility. in as Two X.X findings and of to had have of patients patient tumor lab response. fibrosis are could for for follow-up. Five a in treatment evidence partial studies in blood the for a studies the tumor. CPI-XXX action not ThX An with may are These stable that the patients production therapy on the cells of possible less leading in monitoring overall had additional increase relapsed known to this ThX disease. prior If additional T have serious of weeks XX ThX and three approach cells effects continue patients or is than A assessments. test XXX-milligram cell key cells. study. therapies in underway of of Preclinical survival correlative ThX is Obviously the on
are fibrosis dermatitis, various allergy. culprits secretion A the It like hyperactivity observations other eosinophilia. asthma, pulmonary is High that that diseases made diseases, biomarker eosinophil and as by in we've such ThX counts fibrotic are we counts. addition, our the blood causes diseases. often due circulating lymphoma In us for of blood to XXX pretreatment role in lymphomas. cells diseases ongoing are X atopic allergic is reductions cells In others. are allergic consider patients pertinent ongoing in idiopathic have These white in XXX high our key Phase study baseline cytokines eosinophils known a autoimmune in ThX the of seen use to elevated findings and cells. motivate that patients study, in our with play eosinophils, in of T-cell with several they and in The ThX
autoimmunity. generating are encouraging with in also preclinical XXX We data
division preeminent ASH Rosenbaum, of and and and at is and expand new a and focus the Research Jim? of XXXX where diseases. July. of Q&A arthritis to Oregon advance Medicine us us him and in hired comes specific Sciences introduction in Dr. presented from diseases Professor Biology inflammation as clinical Jim of Chair Board-certified on development our & in in President XXXX. I Some Health of will to ASH immunity. role microbiome He be pass University CPI-XXX. the arthritic the Vice has call of in rheumatic Senior Cell of the been initial enhance rheumatologists immunologist to and order we these the In opportunities, he Jim's with and will and ability portion this a our the autoimmunity deep late experience he the call. of to brief be research previously James for joining to now will served
